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Abstract
Immunotherapy has recently shown important clinical successes in a substantial number of oncology indications.
Additionally, the tumor somatic mutation load has been shown to associate with response to these therapeutic
agents, and specific mutational signatures are hypothesized to improve this association, including signatures related
to pathogen insults. We sought to study in silico the validity of these observations and how they relate to each
other. We first addressed the question whether somatic mutations typically involved in cancer may increase, in a
statistically meaningful manner, the similarity between common pathogens and the human exome. Our study shows
that common mutagenic processes like those resulting from exposure to ultraviolet light (in melanoma) or smoking
(in lung cancer) increase, in the upper range of biologically plausible frequencies, the similarity between cancer
exomes and pathogen DNA at a scale of 12 to 16 nucleotide sequences (corresponding to peptides of 4 − 5 amino
acids). Second, we investigated whether this increased similarity is due to the specific mutation distribution of the
considered mutagenic processes or whether uniformly random mutations at equal rate would trigger the same effect.
Our results show that, depending on the combination of pathogen and mutagenic process, these effects need not be
distinguishable. Third, we studied the impact of mutation rate and showed that increasing mutation rate generally
results in an increased similarity between the cancer exome and pathogen DNA, again at a scale of 4− 5 amino acids.
Finally, we investigated whether the considered mutational processes result in amino-acid changes with functional
relevance that are more likely to be immunogenic. We showed that functional tolerance to mutagenic processes across
species generally suggests more resilience to mutagenic processes that are due to exposure to elements of nature than
to mutagenic processes that are due to exposure to cancer-causing artificial substances. These results support the
idea that recognition of pathogen sequences as well as differential functional tolerance to mutagenic processes may
play an important role in the immune recognition process involved in tumor infiltration by lymphocytes.
Introduction
Recent clinical advances firmly establish the role of immunotherapy (in particular, checkpoint inhibition targetting
the CTLA4 and PD1/PD-L1 pathways [1]) in the treatment of cancer. However, the rates of response vary by
indication, outlining the important role of identifying the patients most likely to respond [2–5]. In parallel, the
analysis of the data in large scale genomic efforts including The Cancer Genome Atlas (TCGA [6]) has identified
universal characteristics of the tumor and its environment that ellicit potential recognition by the host immune system.
In particular, somatic mutational load as inferred by DNA sequencing [7, 8] and cytolytic infiltrate as inferred by
immunohistochemistry or RNA sequencing [9] have emerged as hallmarks of an immune-active tumor enviroment. It
is thus important to understand the causality and mechanism of action that drives the heterogenous composition of
the tumor and its environment and consequently the heterogeneity of response to immunotherapy, in order to select
the right patients for treatment, potential combinations, and potential for early intervention.
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Multiple recent studies have suggested a strong causal link between the mutational burden of the tumor and clinical
response to immunotherapy across multiple indications including Melanoma [10,11], Non Small Cell Lung Cancer [12],
Bladder cancer [13] and Colorectal cancer [14]. In these studies, a strong relationship between neoantigen load (the
number of mutations with immunogenic potential) and response to immunotherapy has been identified. Importantly,
each of these indications are characterized by distinct mutagenic processes that result in abundant neoantigen load
[7, 8]: UV light exposure in Melanoma, smoking in Non Small Cell Lung Cancer, APOBEC activation in Bladder
cancer, and MMR defficiency in MSI-h Colorectal cancer. Whether particular mutations or mutational patterns
preferentially induce an immunologic phenotype remains an open question [10, 11]. However, several hypotheses
have recently been put forward, including the presence of mutations in particular genes [15, 16], or the presence of
a transversion signature related to smoking [12]. In particular, Snyder et al. [11] put forward a hypothesis linking
cancer exomes with patterns present in common pathogens. Namely, their results with exome analysis of Melanoma
patients treated with Ipilimumab, a CTLA4 inhibitor, suggest that somatic mutations in cancer genomes that lead
to tetrapeptides similar to those found in common pathogens are more likely to elicit a response to the therapy than
common somatic mutations. This association is presumably driven by the innate ability of significant portions of the
adaptive immune repertoire to recognize such pathogens.
We took an in-silico approach to evaluate the impact of certain mutagenic processes on the similarity between
cancer exomes and pathogen DNAs. Somatic mutations are an inherent natural process related to cell division and
aging which in some instances is exacerbated by mutagenic factors. We simulated such mutagenic processes using
mixtures of mutational signatures with empirically derived mixing parameters. We used a simple similarity metric
between the mutated exome and common pathogen exomes to estimate changes in overall potential immunogenicity
of cancer exomes as compared to the normal exome. We considered simulations of mutagenic processes that yield
most mutated cancer exomes, namely ultra-violet (UV) light (Melanoma), smoking (Non Small Cell Lung Cancer),
and APOBEC activation (Bladder cancer) [7,9]. Our results suggest that, in the upper range of biologically plausible
mutation rates, mutagenic processes resulting from exposure to these common mutagens lead to cancer exomes that
are more similar pathogen DNAs at a scale of 12 to 16 nucleotides. These changes are subtle but nevertheless
statistically significant and are particularly important in the range of peptide sizes that are relevant for epitope
presentation in the human MHC mechanism; MHC presentation typically involves peptides with lengths between
8-18 nucleotides (8-13 for class I MHC and 13-18 for class II MHC [17]).
However, our results also suggest that the increased similarity need not be caused by the specificity of the
mutation distribution. Depending on the pathogen, uniformly random mutations (at the same rate) may result in
equal increased similarity. Finally, we show that increasing mutation rate generally results in increased similarity
between cancer exomes and pathogen DNAs. These conclusions suggest that mutagenic processes might act as a
mechanism of pressure that models the mutational spectra observed in tumors by increasing recognition from the
host immune system.
Opposite to the aforementioned effect that increases the likelihood that a cancer exome is recognized by the
immune system, an antagonist mechanism of pressure on mutational landscape stems from tolerance by the immune
system to natural mutagenic processes. To that extent, we establish that exomes across species are generally more
resilient, in terms of a functional point of view related to the synonymity of amino-acid changes, to mutagenic
processes that are due to exposure to elements of nature than to mutagenic processes that are due to exposure to
cancer-causing artificial substances. In particular, we observe that the functionality of the genetic code (allocation of
codons to amino-acids) is more resilient to UV light than smoking mutagenic processes at a fixed rate. This suggests
the possibility that there are different tissue-dependent evolutionary tolerance levels, modulated by the pathogen
recognition apparatus in terms of both immune recognition and cancer development, which for example reflect in
the much higher mutational loads and immune infiltrate in Melanoma compared to Lung cancer [9].
1 Methods
We sought to assess whether certain mutagenic processes result in somatic alterations that increase the similarity of
the mutated human exome with selected pathogens. Accordingly, we first defined a pairwise similarity metric among
DNA sequences of different length and evaluated the similarity between pathogens and the normal human exome.
Second, we simulated mutations resulting from different mutagenic processes at different mutation rates acting on
the human exome and evaluated the consequent change in similarity of the mutated human exome with respect to
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the pathogen exomes. Third, we investigated the resiliency of exomes (human exome and model organism exomes)
in terms of maintained functionality of the resulting amino-acids and compared the sequences of amino acids of the
normal and mutated exomes.
Data and computing resources
We obtained the human normal exome from GRCh38 http://www.ensembl.org/Homo_sapiens/Info/Index
We considered the following list of model organisms: Mus Musculus (Mouse), Saccharomyces Cerevisiae (Yeast),
Felis Catus (Cat), Drosophila Melanogaster (Fruitfly), Caenorhabditis Elegans (Nematode), Xenopus, Danio Rerio
(Zebrafish), Cavia Porcellus (Pig), Anolis carolinensis (Anolis). Exomes from these organisms were obtained from
http://uswest.ensembl.org/biomart/martview/
We considered the following list of viral pathogens: Cytomegalovirus (CMV), Dengue virus, Ebola virus, Epstein-
Barr virus (EBV), Human Herpesvirus 6 (HHV), Human Papillomavirus (HPV), Measles virus, Yellow Fever virus.
DNA sequences from these pathogens were obtained from http://www.ncbi.nlm.nih.gov/
We considered simulations of mutational signatures resulting from ultra-violet (UV) light (specific to Melanoma),
smoking (specific to Non Small Cell Lung Cancer (NSCLC)), and APOBEC activation (specific to Bladder cancer).
These simulations were based on the data from [8, Supplementary information, Table S2] restricted to the set of
patients with Melanoma cancer, NSCLC, and Bladder cancer.
For simulations we used Python 2.7.6 (libraries random, numpy, and scipy.stats) and ran programs on a shared
server with 8 CPUs and 128GB memory.
2 Results
2.1 Pathogen DNA vs. human exome and MHC mechanism
To quantify the similarity between a pathogen DNA, denoted by x, and the human exome, denoted by y, we considered
the following similarity score. For a given integer ℓ ≥ 1, the similarity score, denoted by sℓ(x, y), corresponds to the
relative proportion of length-ℓ strings in the pathogen DNA that also appear in the human exome at least once, that
is
sℓ(x, y)
def
=
1
L− ℓ+ 1
L−ℓ+1∑
i=1
zi
where
zi
def
=
{
1 if xi+ℓ−1i ≺ y
0 otherwise.
Here L denotes the length of the pathogen DNA, xi+ℓ−1i
def
= xi, xi+1, . . . , xi+ℓ−1 denotes the pathogen DNA substring
starting at position i and ending at position i + ℓ − 1, and “≺” denotes string inclusion. In particular, sℓ(x, y) = 1
corresponds to the case where all length-ℓ strings in the pathogen DNA also appear in the human exome and
sℓ(x, y) = 0 corresponds to the case where the pathogen DNA and the human exome have no length-ℓ string in
common. Observe that sℓ(x, y) can be interpreted as the probability that a randomly and uniformly picked length-ℓ
string in the pathogen DNA also appears in the human exome. Accordingly, we often refer to sℓ(x, y) as the matching
probability. Finally, notice that sℓ(x, y) does not count multiplicity, i.e., strings that appear only once in the human
exome and strings that appear multiple times in the human exome are note distinguished
In Fig. 1, each curve represents the matching probability sℓ(x, y) for a specific pathogen DNA x and the normal
human exome y, for ℓ ∈ {9, 10, . . . , 18}. To benchmark these scores we also considered the matching probability with
respect to a randomly and uniformly generated “pathogen” sequence, where each nucleotide is equally likely to occur.
The average matching probability with respect to such a sequence is represented by the “Random” curve in Fig. 1
and turns out to be independent of its length L. This curve is indistinguishable from the 95% confidence interval
corresponding to a randomly generated sequence. Supporting material for Fig. 1 is deferred to Section A.1 in the
Appendix. We make the following observations:
⋄ For all pathogens the similarity score is equal to one for ℓ ≤ 10, that is length ℓ ≤ 10 subsequences of the
pathogen DNAs all appear in the human exome as well.
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Figure 1: Each curve represents the matching probability (similarity score) sℓ(x, y) between a pathogen DNA x and
the human exome y, as a function of the subsequence length ℓ. The “Random” curve refers to the average score of
a randomly and uniformly generated “pathogen” DNA sequence.
⋄ The similarity scores are non-zero for all pathogens up to length ℓ = 20. At ℓ = 21 the similarity scores is zero
for the Ebola virus, the Measles virus, and the Dengue virus.
⋄ For all ℓ ∈ {11, . . . , 18} the similarity score for pathogen DNAs is higher than for a random sequence, except
for CMV (ℓ ∈ {15, . . . , 18}) and for HHV (ℓ ∈ {13, . . . , 18}).
⋄ From ℓ = 10 there is a steep decrease in the similarity scores, down to less than 15% for ℓ = 15. A closer look
at the data (see Table A.1.1) reveals that, for all pathogens, the sharpest relative drop of the similarity score
occurs from ℓ = 12 to ℓ = 13 or from ℓ = 13 to ℓ = 14.
⋄ The differences in score across pathogens is maximal at ℓ ∈ {12, 13}.
These in-silico observations are in line with the concept that 4 − 5 amino acids are enough for the presentation
machinery in terms of both diversity of possible sequences (204−205) and differentiation of self from foreign sequences
in the MHC machinery. Namely, this length is strikingly similar to the length of peptides studied in the signature
determined by [11].
2.2 Impact of somatic mutations on pathogen DNA and human exome similarity score
To assess the impact of somatic mutations on pathogen DNA and human exome similarity score and identify the
roles of mutation distribution and mutation rate we proceeded as follows:
• Normal exome vs. cancer exome: we investigated whether cancer somatic mutations render pathogen and
human exome more similar, and whether random mutations alone, with uniform distribution across mutations,
would produce the same results as (typically non-uniform) cancer-dependent mutations, at the same mutation
rate.
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Figure 2: Effects of cancer specific mutations on a normal exome modeled as a cancer channel. Cancer exome
y˜ = {y˜1, y˜2, . . . , y˜G} is obtained from normal exome y = {y1, y2, . . . , yG} through a cancer specific probabilistic
transformation Pc,ρ(β|α) which assigns to each nucleotide α the probability of being mutated to nucleotide β. This
transformation depends on both the mutation distribution specific to cancer c and the mutation rate ρ.
• Impact of mutation rate: we investigated whether a higher mutation rate renders pathogen DNA and human
exome more similar.
Central to our investigation is a notion of cancer channel described next.
Cancer channel
We simulated the changes induced to the normal exome by cancer specific mutagens in a probabilistic way. The
cancer exomes were generated from the normal exome by using cancer-dependent mixtures of mutational signatures
with empirical weights derived from data in [8]. Note that even if a cancer typically exhibits a dominant mutational
signature, the simulated mutagenic process results in a more realistic combination of such signatures. The similarity
scores of the normal exome and cancer exome were then computed for each pathogen. To formalize our analysis,
we used concepts from information theory, in particular related to communications over a noisy channel. To a
given cancer and mutation rate we associated a transformation, referred to as “cancer channel,” which mimics the
typical effects of the mutagenic process that are specific to the cancer at the given mutation rate. Analogously to
a communication channel that alterates a transmitted message because of noise (see, e.g., [18]), a cancer channel
alterates a DNA sequence because of somatic mutations. Given a particular cancer c and a mutation rate ρ the cancer
channel assigns to each nucleotide α the probability Pc,ρ(β|α) of being mutated into nucleotide β. This probability
was derived using data from [8, Supplementary information, Table S2] (see Appendix A.2 in this paper).
To obtain a cancer exome y˜ we “passed” the normal human exome y through cancer channel Pc,ρ(·|·) as shown in
Fig. 2. Specifically, the cancer exome y˜ was generated from y so that the probability to obtain y˜ = {y˜1, y˜2, . . . , y˜G}
from normal exome y = {y1, y2, . . . , yG} was given by
G∏
i=1
Pc,ρ(y˜i|yi).
Normal vs. cancer specific and random mutations
For given pathogen x, cancer c, and mutation rate ρ we performed two tests. In Test 1, we evaluated the statistical
significance of the effect of cancer somatic mutations in making human exome more similar to pathogen DNA
sequences. In Test 2, we compared cancer somatic mutations and random mutations in making the human exome
more similar to pathogen DNA sequences. Both tests were peformed for ρ-values of 0.0005, 0.001, and 0.01. The
lowest mutation rate was chosen to be 0.0005 as it represents a good compromise between biological and statistical
relevance. It lies in the upper range of the mutation rates observed in actual cancer samples [8] and in the lower
range for statistical relevance—see next subsection.
Test 1: For each ℓ ∈ {10, 11, . . . , 18} we independently generated 1000 cancer exomes {y˜} from the normal human
exome y and computed the corresponding similarity scores {sℓ(x, y˜)}. P -values were computed for comparing the
mean of {sℓ(x, y˜)} against sℓ(x, y) using a one-sided t-test with a null hypothesis that the true mean of sℓ(x, y˜) is no
larger than sℓ(x, y).
Test 2: We replaced the cancer channel by a “random channel” which produced mutations at the same rate but
in a uniform (1/3, 1/3, 1/3) manner. For each ℓ ∈ {10, 11, . . . , 18} we independently generated 1000 exomes {yˆ} by
passing the normal human exome y through the random channel and computed the corresponding similarity scores
{sℓ(x, yˆ)}. P -values were computed for comparing the mean of {sℓ(x, yˆ)} against the mean of {sℓ(x, y˜)} (obtained
in Test 1) using a two-sample one-sided t-test with a null hypothesis that the true mean of sℓ(x, y˜) is no larger than
the true mean of sℓ(x, yˆ)—note that directly computing the true mean of sℓ(x, y˜) over y˜ is impossible as it amounts
to computing a sum over all ≈ 4107 possible cancer exomes, and similarly for the mean of sℓ(x, yˆ).
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Melanoma cancer, Mutation rate =0.001
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Melanoma cancer, Mutation rate =0.01
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Figure 3: The height of the red bars represents the proportions of pathogen DNA that are more similar to cancer
exomes than to normal exome (one-sample t-test results with p-value ≤ 0.01). The height of the blue bars represents
the proportion of pathogens whose DNA are more similar to cancer exomes than to exomes with equal mutation rate
but uniformly distributed mutations (two-sample one-sided t-test p-value ≤ 0.01).
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Figure 4: The height of the grey bars represents the proportion of pathogen DNA for which increasing mutation rate
from 0.0005 to 0.001 results in an increased similarity with the cancer exome (p-value≤ 0.01). Orange bars refer to
the same proportions but when mutation rate increases from 0.001 to 0.01.
In Fig. 3, each histogram refers to a particular cancer and mutation rate. Red bars refer to Test 1 and blue
bars refer to Test 2. Bar height represents, for any given subsequence length ℓ ∈ {10, 11, . . . , 18}, the proportion of
pathogens (out of the 8 considered in this paper) for which the p-value is ≤ 0.01. Related data can be found in the
tables of the Appendices A.3 A.4, and A.5 for ρ = 0.0005, ρ = 0.001, and ρ = 0.01, respectively. In these tables,
the second column refers to sℓ(x, y), the third column gives a 95% confidence interval for sℓ(x, y˜), the fourth column
gives the p-value for Test 1 and the fifth column gives the p-value for Test 2. We make the following observations:
⋄ Referring to Test 1 (red bars in Figs. 3), all three mutagenic processes render the human exome more similar
to all pathogen DNA sequences at all ρ ∈ {0.0005, 0.001, 0.01} and ℓ ∈ {12, . . . , 16}. For ℓ ≤ 11 or ℓ ≥ 17 the
effect of the mutagenic processes on the similarity scores are less conclusive. This suggests that the increase of
similarity is particularly relevant in the range of peptide sizes (4− 5 amino-acids) that are relevant for epitope
presentation in the human MHC presentation. Note, however, that the changes in similarity are small, typically
≪ 1% (see tables in Sections A.3-A.5, Columns 2, 3).
⋄ Whether the above change of similarity is due to the specificity of the mutation distribution or random mu-
tations trigger the same effect depends on the pathogen, the length, and the mutation rate. For instance, for
Melanoma at ℓ = 13 the change in similarity due to cancer specific mutations is more pronounced for 5 out of
the 8 pathogens, for ρ ∈ {0.0005, 0.001, 0.01}. By contrast, for all mutagenic processes there appears to be no
statistical difference at length 11.
Impact of mutation rate
To assess the impact of mutational rate on the similarity between pathogen DNA and human exome, for any given
mutagenic process, pathogen DNA, and length we proceeded as follows. We first generated 1000 cancer exomes at
mutation rate ρ = 0.0005 and 1000 cancer exomes at mutation rate 0.001. Second, we computed the similarity scores
of the two sets of cancer exomes relative to the pathogen DNA. P -values were computed for comparing the means of
the two sets of similarity scores using a two-sample one-sided t-test with a null hypothesis that the true mean of the
similarity scores at the lowest rate (ρ = 0.0005) is no larger than the true mean of the similarity scores at the higher
rate (ρ = 0.001). We then repeated the experiment for ρ = 0.001 vs. ρ = 0.01. In Fig. 4, the histograms represent
the proportion of pathogens for which the p-value is ≤ 0.01—grey bars refers to the 0.0005 v.s. 0.001 experiment
and the orange bars refer to the 0.001 v.s. 0.01 experiment. We obtain the following result:
⋄ For all combinations of mutagenic processes and pathogens, and for all ℓ ∈ {11, . . . , 16}, a higher mutation rate
results in higher similarity score. For ℓ ∈ {9, 10, 17, 18} results are inconclusive.
2.3 Resiliency of exomes with respect to mutagenic processes
In order to compare the resiliency of the model organism exomes with respect to mutagenic processes, we evaluated
the error correction capabilities of the genetic code (the codon allocation to amino-acids) for each combination
of model exome and mutagenic process. Referring to Fig. 5, y = {y1, . . . , yL} represents a DNA sequence whose
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{a1, . . . , aL/3} geneticcode
cancer channel
Pc,ρ(·|·)
genetic
code
{y1, . . . , yL} {y˜1, . . . , y˜L} {a˜1, . . . , a˜L/3}
Figure 5: Exome {y1, y2, . . .}, which gives amino acid sequence {a1, a2, . . .}, undergoes specific somatic mutations
through transformation Pc,ρ(·|·) and results in {y˜1, y˜2, . . .} which, in turn, gives amino acid sequence {a˜1, a˜2, . . .}.
corresponding sequence of amino acids is {a1, . . . , aL/3}. This DNA sequence is then passed through a given cancer
channel Pc,ρ(·|·) and results in a cancer sequence y˜ = {y˜1, y˜2, . . . , y˜L} and a corresponding sequence of cancer amino
acids {a˜1, a˜2, . . . , a˜L/3}. From {a1, a2, . . . , aL/3} and {a˜1, a˜2, . . . , a˜L/3} we computed the relative proportion of amino
acids that were affected, that is
|{i : a˜i 6= ai}|
(L/3)
. (1)
Finally, averaging over all possible realizations of y˜ (and therefore over a˜), we obtained the average error probability
P(error|y, c, ρ) = E|{i : a˜i 6= ai}|
(L/3)
. (2)
Fig. 6 represents P(error|y, c, ρ) for each combination of model organism, cancer mutation process, and mutation
rate ρ ∈ {0.0001, 0.001, 0.01}. Notice that P(error|y, c, ρ) is not a linear function of ρ. Computation details for
P(error|y, c, ρ) are deferred to the Appendix A.6. Referring to Fig. 6, we obtain the following result:
⋄ Although the proportion of non-synonymous mutations varies across exomes for the three types of mutagenic
processes, it is always lowest for melanoma and maximal for lung. Moreover, this ordering holds irrespectively
of the intensity of the mutation rate. It should be noted that we evaluated the proportions of non-synonymous
mutations for several other organisms as well (including the set of pathogens considered in this paper) and this
finding was validated in all cases.
3 Discussion
We employed large scale simulations to model the random (across space) effect of stochastic mutagenic processes
on the human normal genome. We believe this is a valid approach since the cancer exome available data does
suggest that, while at the granular level mutation rates vary, the mutagenic processes in cancers with large number
of mutations affect equally all chromosomal regions of the exome [8]. Essentially, we simplify the analysis using this
assumption.
Our in-silico results show that, in general, the typical stochastic mutagenic processes encountered in the major
cancer indications with abundant neoantigens do appear to shift the peptide distribution of the modified exome
universally towards a landscape that appears more similar to pathogenic insult. Specifically, all three mutagenic
processes considered induce subtle but robust shifts in the measure by which we characterized the similarity between
the normal human exome and pathogen DNA sequences, at mutation rates in the upper range of the mutation rates
observed in actual cancer samples (≥ 0.0005). Moreover, the range of peptide lengths where this shift happens
aligns with the typical length of peptides presented by the human MHC presentation system, suggesting an increased
potential for recognition of these types of somatic mutations by a pathogen-trained host immune system.
We also note that for many combinations of pathogen DNA and mutagenic process cases this increase of similarity
cannot be solely attributed to the mutation distribution; randomly and uniformly distributed mutations can cause
similar shifts in similarity. By contrast, increasing the mutation rate while keeping the underlying mutation distri-
bution fixed always results in an increased similarity betweeen human exome and pathogen DNA at ℓ ∈ {11, . . . , 16},
which again corresponds to the length of peptides presented by the human presentation system. This suggests that
PLOS 8 8/32
Plos One, published May 1st 2019, improved formatting 3 DISCUSSION
Human Mouse Yeast Cat Fruitfly Nematode Xenopus Zebrafish Pig Anolis
Organism
0.014%
0.016%
0.018%
0.02%
0.022%
E
rr
o
r 
P
ro
b
a
b
ili
ty
Error probability for mutation rate =0.0001
NSCLC Bladder cancer Melanoma cancer
Human Mouse Yeast Cat Fruitfly Nematode Xenopus Zebrafish Pig Anolis
Organism
0.14%
0.16%
0.18%
0.2%
0.22%
E
rr
o
r 
P
ro
b
a
b
ili
ty
Error probability for mutation rate =0.001
NSCLC Bladder cancer Melanoma cancer
Human Mouse Yeast Cat Fruitfly Nematode Xenopus Zebrafish Pig Anolis
Organism
1.4%
1.6%
1.8%
2.0%
2.2%
E
rr
o
r 
P
ro
b
a
b
ili
ty
Error probability for mutation rate =0.01
NSCLC Bladder cancer Melanoma cancer
Figure 6: Average proportions of erroneous amino acids after passing exomes through different cancer channels at
mutation rater 0.0001, 0.001, and 0.01.
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the intensity of the mutational rate is an important parameter that directly affects the similarity between cancer
exome and pathogen DNA.
We also observe that the effect of the considered mutagenic processes on the likelihood of observing a non-
synonymous alteration is strikingly different across processes but consistent across the species studied in our frame-
work (human and model organisms). Melanoma/UV light alterations are the least likely to result in amino acid
functional changes, followed by APOBEC-driven alterations and then by smoking alterations, suggesting differ-
ent error-correcting capabilities of the living exomes towards this various mutagenic insults. This is an attractive
observation from an evolutionary perspective: due to universal exposure to sunlight, organisms likely developed sim-
ilarly universal intrinsic protection from UV light type of modifications to their exomes via the redundancies in the
aminoacid codon allocation. Similarly, APOBEC-activation appears to be a universal innate protection mechanism
that allows the cell to induce damaging mutations to foreign organisms, while the mutations resulting from tobacco
smoking are less likely to have presented evolutionary pressure. In summary, our in-silico approach reveals two com-
peting mechanisms of tolerance pressure on the major mutagenic processes present in human cancers that modulate
the potential immune recognition of alterations at the exome level through pathogen similarity and through func-
tional redundancy; the balance between these mechanisms may significantly contribute to the eventual mutational
landscape of advanced cancers.
A Appendices
A.1 Data for Fig. 1
In the table below we listed the similarity scores sℓ(x, y) of each pathogen x against the human exome y, as a function
of the subsequence length ℓ.
A.1.1 Matching score of pathogens against human exome
ℓ Ebola virus CMV Dengue virus EBV HHV
9 100.0 100.0 100.0 100.0 100.0
10 99.94 99.71 100.0 99.94 99.83
11 98.11 94.88 99.30 98.26 95.96
12 86.99 74.92 91.65 86.74 79.24
13 56.32 43.52 64.19 58.29 49.20
14 23.94 18.64 29.87 27.43 21.84
15 7.82 6.60 9.98 10.05 7.91
16 2.40 2.23 2.81 3.19 2.73
17 0.62 0.77 0.73 1.02 1.05
18 0.12 0.27 0.19 0.33 0.48
ℓ HPV Measles virus Yellow fever virus Random
9 100.0 100.0 100.0 100±0.002
10 99.97 99.97 100.0 100±0.002
11 99.05 98.23 99.05 96.4±0.002
12 90.48 86.15 92.10 79.4±0.002
13 61.24 54.27 65.28 48.3±0.002
14 28.22 22.64 30.54 20±0.002
15 9.84 7.29 10.81 6.2±0.002
16 3.19 2.19 3.15 1.116±0.001
17 1.10 0.68 0.87 0.28±0.001
18 0.50 0.19 0.29 0.07±0.001
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The column “Random” refers to a 95% confidence interval for the similarity score between a randomly generated
pathogen sequence X , where each nucleotide is independently and uniformly selected with probability 1/4, and the
normal human exome y. To compute this confidence interval we proceeded as follows. The similarity score for a
random instance X of length L is given by
sℓ(X, y) =
1
L− ℓ+ 1
L−ℓ+1∑
i=1
Zi
where the Zi’s are i.i.d. Bernoulli random variables such that
Pr(Zi = 1) = 1− Pr(Zi = 0) = min{1,Mℓ/4ℓ} def= sℓ(y). (3)
Here Mℓ denotes the number of distinct length-ℓ substrings in the human genome and was computed empirically for
ℓ ∈ {9, 10, . . . , 15}:
M9 = 262,144 M10 = 1,047,125 M11 = 4,043,826
M12 = 13,319,884 M13 = 32,427,184 M14 = 53,660,993 M15 = 66,828,678
M16 = 47,945,739 M17 = 49,134,120 M18 = 49,785,872
Taking expectation over X yields
E(sℓ(X, y)) = EZi = sℓ(y).
A confidence inteval for sℓ(X, y) was computed via Chebyshev’s inequality as follows. We have
Pr(|sℓ(X, y)− sℓ(y)| ≥ εℓ) ≤ Var(sℓ(X, y))
ε2ℓ
=
Var(
∑L−ℓ+1
i=1 Zi)
(L− ℓ+ 1)2ε2ℓ
. (4)
Furthermore,
Var(
L−ℓ+1∑
i=1
Zi) =
L−ℓ+1∑
i=1
Var(Zi) + 2
∑
i<j
Cov(Zi, Zj)
= (L− ℓ+ 1)Var(Z1) + 2
L−ℓ+1∑
i=1
i+ℓ−1∑
j=i+1
Cov(Zi, Zj)
where for the second equality we used the fact that the Zi’s are identically distributed and that Zk and Zj are
independent whenever j ≥ k + ℓ. Now
Var(Z1) = sℓ(y)(1− sℓ(y)) ≤ sℓ(y)
and since the Zi’s are binary random variables
Cov(Zi, Zj) = E(ZiZj)− E(Zi)E(Zj)
≤ E(Zi)− E(Zi)E(Zj)
= sℓ(y)(1 − sℓ(y))
≤ sℓ(y).
Therefore,
Var(
L−ℓ+1∑
i=1
Zi) ≤ sℓ(y)(L− ℓ+ 1)(1 + 2(ℓ− 1)). (5)
Finally, from (3), (4), and (5) we get
Pr(|sℓ(X, y)− sℓ(y)| ≥ εℓ) ≤ sℓ(y)(1 + 2(ℓ− 1))
(L − ℓ+ 1)ε2ℓ
=
min{1,M/4ℓ}(1 + 2(ℓ− 1))
(L− ℓ+ 1)ε2ℓ
.
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To obtain a 95% confidence interval we picked
εℓ =
(
min{1,M/4ℓ}(1 + 2(ℓ− 1))
(L− ℓ+ 1)0.05
)1/2
(6)
which is below 0.002 for all ℓ ∈ {9, 10, . . . , 15} regardless of the pathogen length L.
A.2 Cancer channel
We describe how we obtained cancer channel Pc,ρ(·|·) for a given cancer and mutation rate. For each cancer c
(Melanoma cancer, NSCLC, Bladder cancer) we considered the set Sc of patients in [8, Supplementary information,
Table S2] with that cancer. Then, for every mutation α → β we empirically computed the average proportion of
mutations across patients
pc(α→ β) def= 1|Sc|
∑
i∈Sc
pc(i, α→ β)
where pc(i, α→ β) denotes the proportion of α→ β mutations among all mutations in patient i and was computed
from [8, Supplementary information, Table S2]. The probability that a nucleotide α in the normal exome results in
nucleotide β in the cancer exome is therefore given by
Pc,ρ(β|α) = pc(α→ β)ρ
p(α)
for β 6= α and
Pc,ρ(α|α) = 1− ρ
p(α)
∑
β 6=α
pc(α→ β).
The parameter ρ denotes the overall mutation rate and p(α) denotes the relative number of nucleotide α in the exome
and was computed from [8, Supplementary information, Table S2].
Remark. Because in the data from [8, Supplementary information, Table S2] complementary mutations were counted
under the same category (e.g., a change from cytosine to tyamine would be treated the same as a change from guanine
to adenine), mutation types were considered in pairs. Since the relative proportions of complementary pairs were not
given inf, we made the assumption that they were equal. Hence, in the above expression pc(i, α → β, i) actually
corresponds to
pc(i, α→ β, i)/2 + pc(i, α′ → β′, i)/2
where (α′, β′) is the complementary pair of (α, β).
The second column in the tables of Sections A.3-A.5 represents sℓ(x, y) as a function of ℓ. The third column
represents a 95% confidence interval for sℓ(x, y˜) obtained through a standard application of the central limit theorem.
This confidence interval is given by [
sℓ(x)± 1.96σ√
1000
]
,
where sℓ(x) denotes the average of sℓ(x, y˜) over the 1000 independent trials {y˜i}1000i=1 and where σ denotes the empirical
standard deviation of sℓ(x, y˜). The fourth column in the tables of Sections A.3-A.5 gives the p-value for Test 1 and
the fifth column gives the p-value for Test 2.
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A.3 ρ = 0.0005
A.3.1 Ebola virus indication
ℓ Normal Lung, ρ = 0.0005 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 99.94 99.94±0.0002 1.0 < 0.01
11 98.11 98.13±0.0011 < 0.01 0.9999
12 86.99 87.08±0.0022 < 0.01 0.8762
13 56.32 56.45±0.0032 < 0.01 < 0.01
14 23.94 24.03±0.0027 < 0.01 < 0.01
15 7.82 7.86±0.0018 < 0.01 < 0.01
16 2.40 2.41±0.0010 < 0.01 < 0.01
17 0.62 0.63±0.0005 < 0.01 < 0.01
18 0.12 0.12±0.0002 < 0.01 0.4808
ℓ Normal Bladder, ρ = 0.0005 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 99.94 99.94±0.0002 1.0 < 0.01
11 98.11 98.14±0.0012 < 0.01 0.9872
12 86.99 87.08±0.0022 < 0.01 0.8483
13 56.32 56.45±0.0031 < 0.01 < 0.01
14 23.94 24.02±0.0027 < 0.01 < 0.01
15 7.82 7.85±0.0017 < 0.01 < 0.01
16 2.40 2.41±0.0010 < 0.01 < 0.01
17 0.62 0.63±0.0005 < 0.01 0.0831
18 0.12 0.12±0.0003 < 0.01 0.5661
ℓ Normal Mela, ρ = 0.0005 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 99.94 99.94±0.0002 1.0 0.0706
11 98.11 98.13±0.0010 < 0.01 1.0
12 86.99 87.07±0.0021 < 0.01 0.9999
13 56.32 56.46±0.0032 < 0.01 < 0.01
14 23.94 24.03±0.0027 < 0.01 < 0.01
15 7.82 7.86±0.0018 < 0.01 < 0.01
16 2.40 2.41±0.0010 < 0.01 < 0.01
17 0.62 0.63±0.0005 < 0.01 < 0.01
18 0.12 0.12±0.0003 < 0.01 0.5378
A.3.2 CMV indication
ℓ Normal Lung, ρ = 0.0005 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.8501
10 99.71 99.72±0.0001 < 0.01 0.9985
11 94.88 94.94±0.0005 < 0.01 1.0
12 74.92 75.05±0.0008 < 0.01 1.0
13 43.52 43.63±0.0008 < 0.01 1.0
14 18.64 18.70±0.0006 < 0.01 1.0
15 6.60 6.62±0.0004 < 0.01 1.0
16 2.23 2.23±0.0002 < 0.01 0.9999
17 0.77 0.77±0.0001 < 0.01 0.9994
18 0.27 0.27±0.0001 < 0.01 0.9999
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ℓ Normal Bladder, ρ = 0.0005 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.7875
10 99.71 99.72±0.0001 < 0.01 0.0189
11 94.88 94.95±0.0005 < 0.01 0.9999
12 74.92 75.07±0.0008 < 0.01 1.0
13 43.52 43.64±0.0009 < 0.01 1.0
14 18.64 18.70±0.0007 < 0.01 0.9999
15 6.60 6.62±0.0004 < 0.01 0.9999
16 2.23 2.24±0.0003 < 0.01 0.9760
17 0.77 0.77±0.0001 < 0.01 0.8426
18 0.27 0.27±0.0001 < 0.01 0.4867
ℓ Normal Mela, ρ = 0.0005 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.1131
10 99.71 99.72±0.0001 < 0.01 0.9999
11 94.88 94.94±0.0005 < 0.01 1.0
12 74.92 75.04±0.0008 < 0.01 1.0
13 43.52 43.62±0.0008 < 0.01 1.0
14 18.64 18.69±0.0007 < 0.01 1.0
15 6.60 6.61±0.0004 < 0.01 1.0
16 2.23 2.23±0.0002 < 0.01 1.0
17 0.77 0.77±0.0001 < 0.01 0.9999
18 0.27 0.27±0.0001 < 0.01 0.7213
A.3.3 Dengue virus indication
ℓ Normal Lung, ρ = 0.0005 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 100.0 99.98±(< 10−5) 1.0 0.9714
11 99.30 99.29±0.0010 0.9943 0.9994
12 91.65 91.69±0.0026 < 0.01 0.7855
13 64.19 64.29±0.0041 < 0.01 0.1778
14 29.87 29.94±0.0042 < 0.01 < 0.01
15 9.98 10.01±0.0028 < 0.01 0.0106
16 2.81 2.82±0.0016 < 0.01 0.0929
17 0.73 0.74±0.0008 < 0.01 0.2427
18 0.19 0.19±0.0004 < 0.01 0.9153
ℓ Normal Bladder, ρ = 0.0005 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 100.0 99.99±(< 10−5) 1.0 0.8042
11 99.30 99.30±0.0010 < 0.01 0.3967
12 91.65 91.69±0.0026 < 0.01 0.6794
13 64.19 64.29±0.0042 < 0.01 0.1061
14 29.87 29.93±0.0038 < 0.01 0.0510
15 9.98 10.01±0.0026 < 0.01 0.1582
16 2.81 2.82±0.0016 < 0.01 0.1172
17 0.73 0.74±0.0008 < 0.01 0.1540
18 0.19 0.19±0.0004 0.0110 0.9427
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ℓ Normal Mela, ρ = 0.0005 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 100.0 99.99±(< 10−5) 1.0 0.5910
11 99.30 99.29±0.0010 0.9987 0.9998
12 91.65 91.69±0.0027 < 0.01 0.9877
13 64.19 64.29±0.0043 < 0.01 < 0.01
14 29.87 29.94±0.0041 < 0.01 < 0.01
15 9.98 10.02±0.0027 < 0.01 < 0.01
16 2.81 2.82±0.0015 < 0.01 0.0267
17 0.73 0.74±0.0009 < 0.01 0.2552
18 0.19 0.19±0.0005 0.0911 0.9770
A.3.4 EBV indication
ℓ Normal Lung, ρ = 0.0005 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.9525
10 99.94 99.94±(< 10−5) < 0.01 0.9863
11 98.26 98.29±0.0004 < 0.01 1.0
12 86.74 86.82±0.0008 < 0.01 1.0
13 58.29 58.39±0.0011 < 0.01 1.0
14 27.43 27.49±0.0010 < 0.01 1.0
15 10.05 10.07±0.0008 < 0.01 1.0
16 3.19 3.20±0.0005 < 0.01 0.9999
17 1.02 1.02±0.0003 < 0.01 0.9999
18 0.33 0.33±0.0002 < 0.01 0.9997
ℓ Normal Bladder, ρ = 0.0005 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.7931
10 99.94 99.94±(< 10−5) < 0.01 0.2122
11 98.26 98.29±0.0004 < 0.01 0.9999
12 86.74 86.83±0.0009 < 0.01 1.0
13 58.29 58.40±0.0011 < 0.01 1.0
14 27.43 27.49±0.0010 < 0.01 1.0
15 10.05 10.07±0.0008 < 0.01 1.0
16 3.19 3.20±0.0006 < 0.01 0.9999
17 1.02 1.02±0.0003 < 0.01 0.9999
18 0.33 0.33±0.0002 < 0.01 0.9997
ℓ Normal Mela, ρ = 0.0005 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.2818
10 99.94 99.94±(< 10−5) < 0.01 0.9409
11 98.26 98.28±0.0004 < 0.01 1.0
12 86.74 86.82±0.0008 < 0.01 1.0
13 58.29 58.38±0.0011 < 0.01 1.0
14 27.43 27.48±0.0010 < 0.01 1.0
15 10.05 10.06±0.0008 < 0.01 1.0
16 3.19 3.20±0.0005 < 0.01 1.0
17 1.02 1.02±0.0003 < 0.01 1.0
18 0.33 0.33±0.0002 0.8882 0.9999
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A.3.5 HHV indication
ℓ Normal Lung, ρ = 0.0005 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 99.83 99.83±0.0001 < 0.01 0.9998
11 95.96 96.02±0.0006 < 0.01 1.0
12 79.24 79.36±0.0013 < 0.01 1.0
13 49.20 49.32±0.0015 < 0.01 < 0.01
14 21.84 21.91±0.0011 < 0.01 < 0.01
15 7.91 7.94±0.0007 < 0.01 < 0.01
16 2.73 2.74±0.0004 < 0.01 < 0.01
17 1.05 1.05±0.0003 < 0.01 < 0.01
18 0.48 0.48±0.0003 < 0.01 < 0.01
ℓ Normal Bladder, ρ = 0.0005 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.0510
10 99.83 99.83±0.0001 < 0.01 0.9294
11 95.96 96.02±0.0006 < 0.01 0.9999
12 79.24 79.37±0.0014 < 0.01 0.9773
13 49.20 49.32±0.0015 < 0.01 < 0.01
14 21.84 21.91±0.0012 < 0.01 < 0.01
15 7.91 7.94±0.0007 < 0.01 < 0.01
16 2.73 2.74±0.0005 < 0.01 < 0.01
17 1.05 1.05±0.0003 < 0.01 < 0.01
18 0.48 0.48±0.0002 < 0.01 < 0.01
ℓ Normal Mela, ρ = 0.0005 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.7979
10 99.83 99.83±0.0001 < 0.01 0.9999
11 95.96 96.01±0.0006 < 0.01 1.0
12 79.24 79.36±0.0015 < 0.01 1.0
13 49.20 49.32±0.0015 < 0.01 < 0.01
14 21.84 21.91±0.0013 < 0.01 < 0.01
15 7.91 7.94±0.0007 < 0.01 < 0.01
16 2.73 2.74±0.0005 < 0.01 < 0.01
17 1.05 1.05±0.0003 < 0.01 < 0.01
18 0.48 0.48±0.0004 0.0614 0.0148
A.3.6 HPV indication
ℓ Normal Lung, ρ = 0.0005 P-value P-value random
9 100.0 99.98±0.0 1.0 nan
10 99.97 99.96±0.0002 1.0 0.3552
11 99.05 99.04±0.0012 0.9761 0.9939
12 90.48 90.54±0.0032 < 0.01 0.0528
13 61.24 61.37±0.0048 < 0.01 < 0.01
14 28.22 28.30±0.0042 < 0.01 < 0.01
15 9.84 9.88±0.0030 < 0.01 < 0.01
16 3.19 3.20±0.0017 < 0.01 0.0111
17 1.10 1.10±0.0010 < 0.01 0.4128
18 0.50 0.50±0.0006 < 0.01 0.5864
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ℓ Normal Bladder, ρ = 0.0005 P-value P-value random
9 100.0 99.98±0.0 1.0 nan
10 99.97 99.96±0.0002 1.0 0.8341
11 99.05 99.04±0.0011 0.9898 0.9969
12 90.48 90.54±0.0030 < 0.01 0.5926
13 61.24 61.36±0.0049 < 0.01 < 0.01
14 28.22 28.29±0.0040 < 0.01 < 0.01
15 9.84 9.88±0.0029 < 0.01 < 0.01
16 3.19 3.20±0.0017 < 0.01 0.0160
17 1.10 1.10±0.0010 < 0.01 0.8741
18 0.50 0.50±0.0005 < 0.01 0.7670
ℓ Normal Mela, ρ = 0.0005 P-value P-value random
9 100.0 99.98±0.0 1.0 nan
10 99.97 99.96±0.0003 1.0 0.2953
11 99.05 99.04±0.0011 0.9943 0.9980
12 90.48 90.54±0.0030 < 0.01 < 0.01
13 61.24 61.38±0.0046 < 0.01 < 0.01
14 28.22 28.31±0.0041 < 0.01 < 0.01
15 9.84 9.88±0.0030 < 0.01 < 0.01
16 3.19 3.20±0.0018 < 0.01 < 0.01
17 1.10 1.10±0.0010 < 0.01 0.3923
18 0.50 0.50±0.0006 < 0.01 0.6700
A.3.7 Measles virus indication
ℓ Normal Lung, ρ = 0.0005 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 99.97 99.96±0.0002 1.0 0.9512
11 98.23 98.25±0.0012 < 0.01 0.9931
12 86.15 86.24±0.0025 < 0.01 0.0257
13 54.27 54.40±0.0035 < 0.01 < 0.01
14 22.64 22.72±0.0030 < 0.01 < 0.01
15 7.29 7.32±0.0019 < 0.01 < 0.01
16 2.19 2.20±0.0011 < 0.01 0.0878
17 0.68 0.68±0.0006 0.7775 0.9909
18 0.19 0.19±0.0003 0.1692 0.4103
ℓ Normal Bladder, ρ = 0.0005 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 99.97 99.96±0.0002 1.0 0.8931
11 98.23 98.25±0.0012 < 0.01 0.9887
12 86.15 86.24±0.0027 < 0.01 0.6929
13 54.27 54.40±0.0034 < 0.01 0.0118
14 22.64 22.72±0.0029 < 0.01 < 0.01
15 7.29 7.32±0.0020 < 0.01 0.3013
16 2.19 2.20±0.0011 < 0.01 0.4939
17 0.68 0.68±0.0006 0.0737 0.8014
18 0.19 0.19±0.0003 0.6188 0.7503
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ℓ Normal Mela, ρ = 0.0005 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 99.97 99.96±0.0002 1.0 0.9656
11 98.23 98.25±0.0012 < 0.01 0.9999
12 86.15 86.24±0.0025 < 0.01 0.5577
13 54.27 54.40±0.0034 < 0.01 < 0.01
14 22.64 22.72±0.0030 < 0.01 < 0.01
15 7.29 7.32±0.0020 < 0.01 0.1858
16 2.19 2.20±0.0011 < 0.01 0.4911
17 0.68 0.68±0.0006 0.2713 0.9212
18 0.19 0.19±0.0003 0.9773 0.9687
A.3.8 Yellow fever virus indication
ℓ Normal Lung, ρ = 0.0005 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 100.0 99.98±0.0001 1.0 0.7992
11 99.05 99.05±0.0011 < 0.01 0.9959
12 92.10 92.16±0.0028 < 0.01 0.7110
13 65.28 65.38±0.0042 < 0.01 < 0.01
14 30.54 30.61±0.0040 < 0.01 < 0.01
15 10.81 10.83±0.0028 < 0.01 < 0.01
16 3.15 3.16±0.0017 < 0.01 0.3423
17 0.87 0.87±0.0009 < 0.01 0.0814
18 0.29 0.29±0.0005 < 0.01 0.1116
ℓ Normal Bladder, ρ = 0.0005 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 100.0 99.98±0.0001 1.0 0.4066
11 99.05 99.05±0.0011 < 0.01 0.9801
12 92.10 92.16±0.0027 < 0.01 0.7498
13 65.28 65.38±0.0041 < 0.01 0.0445
14 30.54 30.61±0.0042 < 0.01 0.0112
15 10.81 10.83±0.0028 < 0.01 0.2486
16 3.15 3.16±0.0017 < 0.01 0.6824
17 0.87 0.87±0.0009 < 0.01 0.0726
18 0.29 0.29±0.0006 < 0.01 < 0.01
ℓ Normal Mela, ρ = 0.0005 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 100.0 99.98±0.0001 1.0 0.3586
11 99.05 99.05±0.0011 < 0.01 0.9999
12 92.10 92.16±0.0025 < 0.01 0.9998
13 65.28 65.38±0.0043 < 0.01 0.0127
14 30.54 30.61±0.0040 < 0.01 < 0.01
15 10.81 10.83±0.0028 < 0.01 0.0410
16 3.15 3.16±0.0016 < 0.01 0.2823
17 0.87 0.87±0.0009 < 0.01 0.2685
18 0.29 0.29±0.0005 < 0.01 0.0670
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A.4 ρ = 0.001
A.4.1 Ebola virus indication
ℓ Normal Lung, ρ = 0.001 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 99.94 99.94±0.0003 1.0 0.3328
11 98.11 98.16±0.0015 < 0.01 0.9999
12 86.99 87.16±0.0031 < 0.01 0.2037
13 56.32 56.58±0.0045 < 0.01 < 0.01
14 23.94 24.11±0.0040 < 0.01 < 0.01
15 7.82 7.88±0.0025 < 0.01 < 0.01
16 2.40 2.42±0.0014 < 0.01 < 0.01
17 0.62 0.63±0.0008 < 0.01 < 0.01
18 0.12 0.12±0.0004 < 0.01 0.0393
ℓ Normal Bladder, ρ = 0.001 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 99.94 99.94±0.0003 0.9999 < 0.01
11 98.11 98.17±0.0015 < 0.01 0.9999
12 86.99 87.16±0.0031 < 0.01 0.4714
13 56.32 56.57±0.0043 < 0.01 < 0.01
14 23.94 24.10±0.0038 < 0.01 < 0.01
15 7.82 7.88±0.0025 < 0.01 < 0.01
16 2.40 2.42±0.0014 < 0.01 < 0.01
17 0.62 0.63±0.0008 < 0.01 < 0.01
18 0.12 0.12±0.0004 < 0.01 0.0521
ℓ Normal Mela, ρ = 0.001 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 99.94 99.94±0.0002 1.0 0.8304
11 98.11 98.16±0.0015 < 0.01 1.0
12 86.99 87.15±0.0032 < 0.01 0.9989
13 56.32 56.59±0.0045 < 0.01 < 0.01
14 23.94 24.12±0.0039 < 0.01 < 0.01
15 7.82 7.89±0.0025 < 0.01 < 0.01
16 2.40 2.42±0.0014 < 0.01 < 0.01
17 0.62 0.63±0.0007 < 0.01 < 0.01
18 0.12 0.12±0.0004 < 0.01 0.1217
A.4.2 CMV indication
ℓ Normal Lung, ρ = 0.001 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.6082
10 99.71 99.73±0.0002 < 0.01 0.9999
11 94.88 95.01±0.0007 < 0.01 1.0
12 74.92 75.18±0.0011 < 0.01 1.0
13 43.52 43.74±0.0012 < 0.01 1.0
14 18.64 18.75±0.0010 < 0.01 1.0
15 6.60 6.63±0.0006 < 0.01 1.0
16 2.23 2.24±0.0003 < 0.01 1.0
17 0.77 0.77±0.0002 < 0.01 0.9999
18 0.27 0.27±0.0001 < 0.01 0.9987
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ℓ Normal Bladder, ρ = 0.001 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5183
10 99.71 99.73±0.0002 < 0.01 0.0255
11 94.88 95.02±0.0007 < 0.01 0.9999
12 74.92 75.21±0.0011 < 0.01 1.0
13 43.52 43.76±0.0012 < 0.01 1.0
14 18.64 18.76±0.0010 < 0.01 1.0
15 6.60 6.64±0.0007 < 0.01 0.9999
16 2.23 2.24±0.0004 < 0.01 0.9999
17 0.77 0.77±0.0002 < 0.01 0.5676
18 0.27 0.27±0.0001 < 0.01 0.3313
ℓ Normal Mela, ρ = 0.001 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.7682
10 99.71 99.73±0.0002 < 0.01 0.9999
11 94.88 95.00±0.0007 < 0.01 1.0
12 74.92 75.16±0.0011 < 0.01 1.0
13 43.52 43.72±0.0012 < 0.01 1.0
14 18.64 18.73±0.0010 < 0.01 1.0
15 6.60 6.63±0.0006 < 0.01 1.0
16 2.23 2.24±0.0004 < 0.01 1.0
17 0.77 0.77±0.0002 < 0.01 0.9999
18 0.27 0.27±0.0001 < 0.01 0.7692
A.4.3 Dengue virus indication
ℓ Normal Lung, ρ = 0.001 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 100.0 99.98±(< 10−5) 1.0 0.3914
11 99.30 99.31±0.0014 < 0.01 0.9896
12 91.65 91.75±0.0038 < 0.01 0.9918
13 64.19 64.40±0.0060 < 0.01 < 0.01
14 29.87 30.01±0.0056 < 0.01 < 0.01
15 9.98 10.04±0.0039 < 0.01 < 0.01
16 2.81 2.83±0.0023 < 0.01 < 0.01
17 0.73 0.74±0.0012 < 0.01 0.4424
18 0.19 0.19±0.0005 0.0456 0.9791
ℓ Normal Bladder, ρ = 0.001 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 100.0 99.98±0.0001 1.0 0.8145
11 99.30 99.31±0.0014 < 0.01 0.9694
12 91.65 91.75±0.0036 < 0.01 0.9986
13 64.19 64.39±0.0059 < 0.01 < 0.01
14 29.87 30.01±0.0057 < 0.01 < 0.01
15 9.98 10.04±0.0039 < 0.01 < 0.01
16 2.81 2.83±0.0021 < 0.01 0.0433
17 0.73 0.74±0.0012 < 0.01 0.5961
18 0.19 0.19±0.0006 < 0.01 0.8638
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ℓ Normal Mela, ρ = 0.001 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 100.0 99.98±(< 10−5) 1.0 0.4457
11 99.30 99.30±0.0013 < 0.01 0.9999
12 91.65 91.75±0.0035 < 0.01 0.9999
13 64.19 64.41±0.0061 < 0.01 < 0.01
14 29.87 30.02±0.0055 < 0.01 < 0.01
15 9.98 10.05±0.0037 < 0.01 < 0.01
16 2.81 2.83±0.0023 < 0.01 0.2108
17 0.73 0.74±0.0012 < 0.01 0.3675
18 0.19 0.19±0.0006 < 0.01 0.7893
A.4.4 EBV indication
ℓ Normal Lung, ρ = 0.001 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.1418
10 99.94 99.95±0.0001 < 0.01 0.7993
11 98.26 98.31±0.0005 < 0.01 1.0
12 86.74 86.91±0.0012 < 0.01 1.0
13 58.29 58.49±0.0016 < 0.01 1.0
14 27.43 27.54±0.0015 < 0.01 1.0
15 10.05 10.08±0.0012 < 0.01 1.0
16 3.19 3.20±0.0008 < 0.01 1.0
17 1.02 1.03±0.0004 < 0.01 0.9999
18 0.33 0.33±0.0002 < 0.01 0.9999
ℓ Normal Bladder, ρ = 0.001 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.2185
10 99.94 99.95±0.0001 < 0.01 0.1288
11 98.26 98.31±0.0005 < 0.01 0.9999
12 86.74 86.92±0.0012 < 0.01 1.0
13 58.29 58.50±0.0016 < 0.01 1.0
14 27.43 27.55±0.0014 < 0.01 1.0
15 10.05 10.09±0.0012 < 0.01 1.0
16 3.19 3.20±0.0008 < 0.01 1.0
17 1.02 1.03±0.0004 < 0.01 0.9999
18 0.33 0.33±0.0003 < 0.01 0.9999
ℓ Normal Mela, ρ = 0.001 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.0412
10 99.94 99.95±0.0001 < 0.01 0.9878
11 98.26 98.31±0.0005 < 0.01 1.0
12 86.74 86.90±0.0012 < 0.01 1.0
13 58.29 58.47±0.0016 < 0.01 1.0
14 27.43 27.52±0.0014 < 0.01 1.0
15 10.05 10.07±0.0011 < 0.01 1.0
16 3.19 3.20±0.0008 < 0.01 1.0
17 1.02 1.02±0.0004 < 0.01 1.0
18 0.33 0.33±0.0002 0.9238 1.0
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A.4.5 HHV indication
ℓ Normal Lung, ρ = 0.001 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.2959
10 99.83 99.84±0.0002 < 0.01 1.0
11 95.96 96.07±0.0008 < 0.01 1.0
12 79.24 79.48±0.0018 < 0.01 1.0
13 49.20 49.45±0.0021 < 0.01 < 0.01
14 21.84 21.98±0.0018 < 0.01 < 0.01
15 7.91 7.97±0.0010 < 0.01 < 0.01
16 2.73 2.75±0.0007 < 0.01 < 0.01
17 1.05 1.06±0.0005 < 0.01 < 0.01
18 0.48 0.48±0.0004 < 0.01 < 0.01
ℓ Normal Bladder, ρ = 0.001 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5000
10 99.83 99.84±0.0002 < 0.01 0.9739
11 95.96 96.08±0.0008 < 0.01 1.0
12 79.24 79.49±0.0018 < 0.01 0.9999
13 49.20 49.45±0.0023 < 0.01 < 0.01
14 21.84 21.98±0.0018 < 0.01 < 0.01
15 7.91 7.97±0.0010 < 0.01 < 0.01
16 2.73 2.75±0.0007 < 0.01 < 0.01
17 1.05 1.06±0.0004 < 0.01 < 0.01
18 0.48 0.48±0.0005 < 0.01 < 0.01
ℓ Normal Mela, ρ = 0.001 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.8155
10 99.83 99.84±0.0002 < 0.01 1.0
11 95.96 96.06±0.0008 < 0.01 1.0
12 79.24 79.47±0.0020 < 0.01 1.0
13 49.20 49.45±0.0022 < 0.01 < 0.01
14 21.84 21.99±0.0017 < 0.01 < 0.01
15 7.91 7.97±0.0011 < 0.01 < 0.01
16 2.73 2.75±0.0007 < 0.01 < 0.01
17 1.05 1.06±0.0004 < 0.01 < 0.01
18 0.48 0.48±0.0005 < 0.01 < 0.01
A.4.6 HPV indication
ℓ Normal Lung, ρ = 0.001 P-value P-value random
9 100.0 99.98±(< 10−5) 1.0 0.5
10 99.97 99.96±0.0004 1.0 0.4823
11 99.05 99.05±0.0016 < 0.01 0.9992
12 90.48 90.61±0.0044 < 0.01 0.0447
13 61.24 61.48±0.0068 < 0.01 < 0.01
14 28.22 28.39±0.0062 < 0.01 < 0.01
15 9.84 9.91±0.0042 < 0.01 < 0.01
16 3.19 3.22±0.0024 < 0.01 < 0.01
17 1.10 1.11±0.0015 < 0.01 0.0765
18 0.50 0.50±0.0009 < 0.01 0.3499
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ℓ Normal Bladder, ρ = 0.001 P-value P-value random
9 100.0 99.98±(< 10−5) 1.0 0.5
10 99.97 99.96±0.0003 1.0 0.2536
11 99.05 99.06±0.0016 < 0.01 0.9969
12 90.48 90.61±0.0044 < 0.01 0.2479
13 61.24 61.47±0.0067 < 0.01 < 0.01
14 28.22 28.38±0.0061 < 0.01 < 0.01
15 9.84 9.91±0.0040 < 0.01 < 0.01
16 3.19 3.21±0.0025 < 0.01 < 0.01
17 1.10 1.10±0.0014 < 0.01 0.4720
18 0.50 0.50±0.0008 < 0.01 0.8303
ℓ Normal Mela, ρ = 0.001 P-value P-value random
9 100.0 99.98±(< 10−5) 1.0 0.5
10 99.97 99.96±0.0003 1.0 0.4093
11 99.05 99.05±0.0016 < 0.01 0.9998
12 90.48 90.62±0.0043 < 0.01 < 0.01
13 61.24 61.50±0.0069 < 0.01 < 0.01
14 28.22 28.40±0.0059 < 0.01 < 0.01
15 9.84 9.92±0.0040 < 0.01 < 0.01
16 3.19 3.22±0.0025 < 0.01 < 0.01
17 1.10 1.11±0.0014 < 0.01 0.0188
18 0.50 0.50±0.0008 < 0.01 0.3983
A.4.7 Measles virus indication
ℓ Normal Lung, ρ = 0.001 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 99.97 99.97±0.0003 1.0 0.4318
11 98.23 98.28±0.0017 < 0.01 0.9998
12 86.15 86.34±0.0036 < 0.01 0.5411
13 54.27 54.53±0.0050 < 0.01 < 0.01
14 22.64 22.79±0.0043 < 0.01 < 0.01
15 7.29 7.34±0.0028 < 0.01 0.1535
16 2.19 2.20±0.0015 < 0.01 0.3683
17 0.68 0.68±0.0008 0.0104 0.4496
18 0.19 0.19±0.0004 0.9896 0.7992
ℓ Normal Bladder, ρ = 0.001 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 99.97 99.97±0.0003 1.0 0.3667
11 98.23 98.28±0.0017 < 0.01 0.9969
12 86.15 86.34±0.0035 < 0.01 0.1666
13 54.27 54.52±0.0050 < 0.01 < 0.01
14 22.64 22.78±0.0042 < 0.01 < 0.01
15 7.29 7.34±0.0029 < 0.01 0.9235
16 2.19 2.20±0.0016 < 0.01 0.5732
17 0.68 0.68±0.0009 0.2049 0.7833
18 0.19 0.19±0.0004 0.3444 0.1426
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ℓ Normal Mela, ρ = 0.001 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 99.97 99.97±0.0002 1.0 0.1908
11 98.23 98.27±0.0015 < 0.01 0.9999
12 86.15 86.34±0.0037 < 0.01 0.9581
13 54.27 54.53±0.0047 < 0.01 < 0.01
14 22.64 22.78±0.0041 < 0.01 < 0.01
15 7.29 7.34±0.0027 < 0.01 0.9399
16 2.19 2.20±0.0016 < 0.01 0.2985
17 0.68 0.68±0.0009 0.3218 0.8489
18 0.19 0.19±0.0004 0.8608 0.4713
A.4.8 Yellow fever virus indication
ℓ Normal Lung, ρ = 0.001 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 100.0 99.98±0.0001 1.0 0.9805
11 99.05 99.07±0.0015 < 0.01 0.9999
12 92.10 92.21±0.0038 < 0.01 0.9061
13 65.28 65.48±0.0059 < 0.01 0.6362
14 30.54 30.68±0.0056 < 0.01 0.1009
15 10.81 10.86±0.0040 < 0.01 0.2397
16 3.15 3.17±0.0024 < 0.01 0.7796
17 0.87 0.87±0.0013 < 0.01 0.0412
18 0.29 0.29±0.0007 < 0.01 0.1197
ℓ Normal Bladder, ρ = 0.001 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 100.0 99.98±0.0001 1.0 0.9826
11 99.05 99.07±0.0015 < 0.01 0.8695
12 92.10 92.21±0.0038 < 0.01 0.9591
13 65.28 65.47±0.0062 < 0.01 0.8768
14 30.54 30.67±0.0058 < 0.01 0.6535
15 10.81 10.85±0.0040 < 0.01 0.3259
16 3.15 3.17±0.0024 < 0.01 0.7424
17 0.87 0.88±0.0013 < 0.01 < 0.01
18 0.29 0.29±0.0008 < 0.01 0.0134
ℓ Normal Mela, ρ = 0.001 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 100.0 99.98±0.0001 1.0 0.9725
11 99.05 99.06±0.0015 < 0.01 0.9999
12 92.10 92.20±0.0038 < 0.01 0.9993
13 65.28 65.48±0.0059 < 0.01 0.4637
14 30.54 30.68±0.0057 < 0.01 0.1347
15 10.81 10.86±0.0039 < 0.01 0.0967
16 3.15 3.17±0.0023 < 0.01 0.0534
17 0.87 0.87±0.0014 < 0.01 < 0.01
18 0.29 0.29±0.0007 < 0.01 0.0580
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A.5 ρ = 0.01
A.5.1 Ebola virus indication
ℓ Normal Lung, ρ = 0.01 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 99.94 99.96±0.0005 < 0.01 0.9989
11 98.11 98.61±0.0035 < 0.01 1.0
12 86.99 88.54±0.0080 < 0.01 0.9074
13 56.32 58.74±0.0125 < 0.01 < 0.01
14 23.94 25.48±0.0119 < 0.01 < 0.01
15 7.82 8.41±0.0079 < 0.01 < 0.01
16 2.40 2.57±0.0045 < 0.01 < 0.01
17 0.62 0.68±0.0025 < 0.01 < 0.01
18 0.12 0.14±0.0013 < 0.01 0.0210
ℓ Normal Bladder, ρ = 0.01 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 99.94 99.96±0.0005 < 0.01 0.8464
11 98.11 98.62±0.0036 < 0.01 1.0
12 86.99 88.54±0.0083 < 0.01 0.8328
13 56.32 58.63±0.0124 < 0.01 < 0.01
14 23.94 25.40±0.0112 < 0.01 < 0.01
15 7.82 8.38±0.0076 < 0.01 < 0.01
16 2.40 2.56±0.0044 < 0.01 < 0.01
17 0.62 0.68±0.0024 < 0.01 < 0.01
18 0.12 0.14±0.0013 < 0.01 < 0.01
ℓ Normal Mela, ρ = 0.01 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 1.0
10 99.94 99.96±0.0005 < 0.01 0.9999
11 98.11 98.55±0.0035 < 0.01 1.0
12 86.99 88.45±0.0081 < 0.01 1.0
13 56.32 58.78±0.0130 < 0.01 < 0.01
14 23.94 25.58±0.0113 < 0.01 < 0.01
15 7.82 8.46±0.0075 < 0.01 < 0.01
16 2.40 2.59±0.0044 < 0.01 < 0.01
17 0.62 0.68±0.0024 < 0.01 < 0.01
18 0.12 0.14±0.0013 < 0.01 < 0.01
A.5.2 CMV indication
ℓ Normal Lung, ρ = 0.01 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.4631
10 99.71 99.84±0.0004 < 0.01 1.0
11 94.88 95.97±0.0017 < 0.01 1.0
12 74.92 77.22±0.0031 < 0.01 1.0
13 43.52 45.49±0.0035 < 0.01 1.0
14 18.64 19.54±0.0029 < 0.01 1.0
15 6.60 6.89±0.0019 < 0.01 1.0
16 2.23 2.31±0.0011 < 0.01 1.0
17 0.77 0.79±0.0007 < 0.01 1.0
18 0.27 0.28±0.0004 < 0.01 1.0
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ℓ Normal Bladder, ρ = 0.01 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.1164
10 99.71 99.85±0.0004 < 0.01 0.2682
11 94.88 96.06±0.0017 < 0.01 1.0
12 74.92 77.45±0.0031 < 0.01 1.0
13 43.52 45.67±0.0036 < 0.01 1.0
14 18.64 19.63±0.0029 < 0.01 1.0
15 6.60 6.93±0.0020 < 0.01 1.0
16 2.23 2.33±0.0012 < 0.01 1.0
17 0.77 0.79±0.0007 < 0.01 0.9999
18 0.27 0.28±0.0004 < 0.01 0.9996
ℓ Normal Mela, ρ = 0.01 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.4026
10 99.71 99.83±0.0004 < 0.01 1.0
11 94.88 95.88±0.0017 < 0.01 1.0
12 74.92 76.94±0.0032 < 0.01 1.0
13 43.52 45.20±0.0036 < 0.01 1.0
14 18.64 19.39±0.0029 < 0.01 1.0
15 6.60 6.84±0.0020 < 0.01 1.0
16 2.23 2.30±0.0011 < 0.01 1.0
17 0.77 0.78±0.0007 < 0.01 1.0
18 0.27 0.28±0.0004 < 0.01 0.9999
A.5.3 Dengue virus indication
ℓ Normal Lung, ρ = 0.01 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 100.0 99.98±0.0002 1.0 0.9511
11 99.30 99.45±0.0033 < 0.01 1.0
12 91.65 92.69±0.0094 < 0.01 0.9996
13 64.19 66.20±0.0159 < 0.01 < 0.01
14 29.87 31.21±0.0169 < 0.01 < 0.01
15 9.98 10.52±0.0119 < 0.01 < 0.01
16 2.81 2.99±0.0072 < 0.01 < 0.01
17 0.73 0.78±0.0035 < 0.01 0.0167
18 0.19 0.20±0.0019 < 0.01 0.9490
ℓ Normal Bladder, ρ = 0.01 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 100.0 99.98±0.0002 1.0 0.3175
11 99.30 99.47±0.0033 < 0.01 0.9999
12 91.65 92.69±0.0094 < 0.01 0.9999
13 64.19 66.12±0.0163 < 0.01 < 0.01
14 29.87 31.12±0.0166 < 0.01 < 0.01
15 9.98 10.49±0.0114 < 0.01 < 0.01
16 2.81 2.97±0.0066 < 0.01 < 0.01
17 0.73 0.78±0.0037 < 0.01 0.6529
18 0.19 0.20±0.0018 < 0.01 0.9154
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ℓ Normal Mela, ρ = 0.01 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 < 0.01
10 100.0 99.98±0.0002 1.0 0.9623
11 99.30 99.43±0.0032 < 0.01 1.0
12 91.65 92.60±0.0094 < 0.01 1.0
13 64.19 66.19±0.0168 < 0.01 < 0.01
14 29.87 31.23±0.0163 < 0.01 < 0.01
15 9.98 10.53±0.0114 < 0.01 < 0.01
16 2.81 2.98±0.0068 < 0.01 < 0.01
17 0.73 0.78±0.0035 < 0.01 0.8850
18 0.19 0.20±0.0019 < 0.01 0.9918
A.5.4 EBV indication
ℓ Normal Lung, ρ = 0.01 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.4341
10 99.94 99.97±0.0002 < 0.01 0.9999
11 98.26 98.69±0.0013 < 0.01 1.0
12 86.74 88.26±0.0032 < 0.01 1.0
13 58.29 60.10±0.0047 < 0.01 1.0
14 27.43 28.38±0.0043 < 0.01 1.0
15 10.05 10.34±0.0033 < 0.01 1.0
16 3.19 3.28±0.0025 < 0.01 1.0
17 1.02 1.04±0.0014 < 0.01 1.0
18 0.33 0.33±0.0008 < 0.01 1.0
ℓ Normal Bladder, ρ = 0.01 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.1901
10 99.94 99.97±0.0002 < 0.01 0.2963
11 98.26 98.71±0.0012 < 0.01 1.0
12 86.74 88.35±0.0033 < 0.01 1.0
13 58.29 60.16±0.0046 < 0.01 1.0
14 27.43 28.42±0.0044 < 0.01 1.0
15 10.05 10.37±0.0034 < 0.01 1.0
16 3.19 3.29±0.0024 < 0.01 1.0
17 1.02 1.05±0.0015 < 0.01 1.0
18 0.33 0.33±0.0010 < 0.01 1.0
ℓ Normal Mela, ρ = 0.01 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.3681
10 99.94 99.97±0.0002 < 0.01 1.0
11 98.26 98.66±0.0013 < 0.01 1.0
12 86.74 88.11±0.0033 < 0.01 1.0
13 58.29 59.85±0.0046 < 0.01 1.0
14 27.43 28.16±0.0042 < 0.01 1.0
15 10.05 10.23±0.0033 < 0.01 1.0
16 3.19 3.24±0.0022 < 0.01 1.0
17 1.02 1.03±0.0013 < 0.01 1.0
18 0.33 0.32±0.0008 1.0 1.0
PLOS 27 27/32
Plos One, published May 1st 2019, improved formatting A APPENDICES
A.5.5 HHV indication
ℓ Normal Lung, ρ = 0.01 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.7781
10 99.83 99.90±0.0004 < 0.01 1.0
11 95.96 96.87±0.0020 < 0.01 1.0
12 79.24 81.36±0.0050 < 0.01 1.0
13 49.20 51.48±0.0060 < 0.01 < 0.01
14 21.84 23.18±0.0050 < 0.01 < 0.01
15 7.91 8.42±0.0031 < 0.01 < 0.01
16 2.73 2.89±0.0021 < 0.01 < 0.01
17 1.05 1.09±0.0015 < 0.01 < 0.01
18 0.48 0.49±0.0017 < 0.01 < 0.01
ℓ Normal Bladder, ρ = 0.01 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5638
10 99.83 99.90±0.0004 < 0.01 0.9999
11 95.96 96.93±0.0021 < 0.01 1.0
12 79.24 81.48±0.0051 < 0.01 1.0
13 49.20 51.50±0.0067 < 0.01 < 0.01
14 21.84 23.15±0.0051 < 0.01 < 0.01
15 7.91 8.41±0.0033 < 0.01 < 0.01
16 2.73 2.89±0.0021 < 0.01 < 0.01
17 1.05 1.10±0.0016 < 0.01 < 0.01
18 0.48 0.49±0.0017 < 0.01 < 0.01
ℓ Normal Mela, ρ = 0.01 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.8672
10 99.83 99.89±0.0004 < 0.01 1.0
11 95.96 96.79±0.0021 < 0.01 1.0
12 79.24 81.22±0.0052 < 0.01 1.0
13 49.20 51.50±0.0069 < 0.01 < 0.01
14 21.84 23.26±0.0055 < 0.01 < 0.01
15 7.91 8.48±0.0034 < 0.01 < 0.01
16 2.73 2.91±0.0022 < 0.01 < 0.01
17 1.05 1.11±0.0015 < 0.01 < 0.01
18 0.48 0.49±0.0017 < 0.01 < 0.01
A.5.6 HPV indication
ℓ Normal Lung, ρ = 0.01 P-value P-value random
9 100.0 99.98±(< 10−5) 1.0 0.1587
10 99.97 99.96±0.0007 1.0 0.9984
11 99.05 99.23±0.0039 < 0.01 0.9999
12 90.48 91.75±0.0114 < 0.01 < 0.01
13 61.24 63.56±0.0183 < 0.01 < 0.01
14 28.22 29.77±0.0175 < 0.01 < 0.01
15 9.84 10.55±0.0124 < 0.01 < 0.01
16 3.19 3.45±0.0076 < 0.01 < 0.01
17 1.10 1.19±0.0046 < 0.01 < 0.01
18 0.50 0.53±0.0025 < 0.01 < 0.01
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ℓ Normal Bladder, ρ = 0.01 P-value P-value random
9 100.0 99.98±(< 10−5) 1.0 0.5
10 99.97 99.97±0.0007 1.0 0.9724
11 99.05 99.24±0.0039 < 0.01 0.9999
12 90.48 91.71±0.0111 < 0.01 < 0.01
13 61.24 63.34±0.0182 < 0.01 < 0.01
14 28.22 29.65±0.0180 < 0.01 < 0.01
15 9.84 10.48±0.0121 < 0.01 < 0.01
16 3.19 3.43±0.0072 < 0.01 < 0.01
17 1.10 1.17±0.0042 < 0.01 < 0.01
18 0.50 0.52±0.0024 < 0.01 0.5377
ℓ Normal Mela, ρ = 0.01 P-value P-value random
9 100.0 99.98±(< 10−5) 1.0 0.1587
10 99.97 99.96±0.0007 1.0 0.9999
11 99.05 99.21±0.0038 < 0.01 1.0
12 90.48 91.77±0.0115 < 0.01 < 0.01
13 61.24 63.70±0.0181 < 0.01 < 0.01
14 28.22 29.96±0.0179 < 0.01 < 0.01
15 9.84 10.64±0.0124 < 0.01 < 0.01
16 3.19 3.48±0.0072 < 0.01 < 0.01
17 1.10 1.19±0.0043 < 0.01 < 0.01
18 0.50 0.53±0.0025 < 0.01 < 0.01
A.5.7 Measles virus indication
ℓ Normal Lung, ρ = 0.01 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 99.97 99.98±0.0004 < 0.01 0.9998
11 98.23 98.70±0.0037 < 0.01 1.0
12 86.15 87.87±0.0094 < 0.01 0.9934
13 54.27 56.70±0.0140 < 0.01 < 0.01
14 22.64 23.98±0.0127 < 0.01 < 0.01
15 7.29 7.73±0.0084 < 0.01 < 0.01
16 2.19 2.29±0.0049 < 0.01 0.5766
17 0.68 0.69±0.0027 < 0.01 0.3373
18 0.19 0.19±0.0013 0.5424 0.0179
ℓ Normal Bladder, ρ = 0.01 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 99.97 99.98±0.0004 < 0.01 0.9992
11 98.23 98.71±0.0037 < 0.01 1.0
12 86.15 87.88±0.0091 < 0.01 0.3703
13 54.27 56.57±0.0138 < 0.01 < 0.01
14 22.64 23.86±0.0124 < 0.01 < 0.01
15 7.29 7.69±0.0078 < 0.01 0.5972
16 2.19 2.28±0.0049 < 0.01 0.9990
17 0.68 0.69±0.0026 < 0.01 0.7406
18 0.19 0.19±0.0014 0.5426 0.0220
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ℓ Normal Mela, ρ = 0.01 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 1.0
10 99.97 99.98±0.0004 < 0.01 0.9999
11 98.23 98.65±0.0038 < 0.01 1.0
12 86.15 87.81±0.0096 < 0.01 1.0
13 54.27 56.61±0.0131 < 0.01 < 0.01
14 22.64 23.92±0.0121 < 0.01 < 0.01
15 7.29 7.71±0.0082 < 0.01 0.0134
16 2.19 2.27±0.0048 < 0.01 0.9999
17 0.68 0.68±0.0026 0.0137 0.9609
18 0.19 0.19±0.0014 0.9999 0.9017
A.5.8 Yellow fever virus indication
ℓ Normal Lung, ρ = 0.01 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 100.0 99.98±0.0002 1.0 0.6664
11 99.05 99.30±0.0034 < 0.01 1.0
12 92.10 93.10±0.0094 < 0.01 1.0
13 65.28 67.19±0.0169 < 0.01 < 0.01
14 30.54 31.81±0.0176 < 0.01 < 0.01
15 10.81 11.26±0.0119 < 0.01 < 0.01
16 3.15 3.32±0.0070 < 0.01 0.3854
17 0.87 0.94±0.0039 < 0.01 < 0.01
18 0.29 0.31±0.0022 < 0.01 < 0.01
ℓ Normal Bladder, ρ = 0.01 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 0.5
10 100.0 99.98±0.0003 1.0 0.9609
11 99.05 99.30±0.0034 < 0.01 0.9999
12 92.10 93.11±0.0096 < 0.01 0.9999
13 65.28 67.09±0.0173 < 0.01 0.9999
14 30.54 31.75±0.0164 < 0.01 0.0112
15 10.81 11.25±0.0116 < 0.01 0.0579
16 3.15 3.32±0.0068 < 0.01 0.1432
17 0.87 0.94±0.0038 < 0.01 < 0.01
18 0.29 0.32±0.0023 < 0.01 < 0.01
ℓ Normal Mela, ρ = 0.01 P-value P-value random
9 100.0 99.99±(< 10−5) 1.0 < 0.01
10 100.0 99.98±0.0003 1.0 0.9888
11 99.05 99.26±0.0036 < 0.01 1.0
12 92.10 93.01±0.0090 < 0.01 1.0
13 65.28 67.03±0.0170 < 0.01 1.0
14 30.54 31.77±0.0166 < 0.01 < 0.01
15 10.81 11.26±0.0121 < 0.01 < 0.01
16 3.15 3.33±0.0073 < 0.01 < 0.01
17 0.87 0.95±0.0040 < 0.01 < 0.01
18 0.29 0.32±0.0023 < 0.01 < 0.01
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A.6 Error probability data for Fig. 6
To compute E|{i : a˜i 6= ai}| in (2) we proceeded as follows. We have
E|{i : a˜i 6= ai}| =
∑
i
P(a˜i 6= ai) (7)
where the summation ranges over amino acid positions. Let us compute P(a˜1 6= a1)—for the other terms we proceed
in the same way. Observe that a1 is a function of the first three nucleotides y1, y2, y3 of the normal exome y. To
emphasize this, let us write a1 as a1(y1, y2, y3). Similarly, a˜1 is a function of the first three nucleotides y˜1, y˜2, y˜3 of
the cancer genome y˜ and we write it as a˜1(y˜1, y˜2, y˜3). Therefore, we have
P(a˜1 6= a1) =
∑
(y˜1,y˜2,y˜3):
a˜1(y˜1,y˜2,y˜3) 6=a1(y1,y2,y3)
3∏
j=1
Pc,ρ(y˜j |yj) (8)
where Pc,ρ(y˜j |yj) is the cancer channel defined in the Appendix A.2.
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